A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
| 适应症 | Type 2 Diabetes Mellitus |
|---|---|
| 分期 | 3期 |
| 申办方 | Eli Lilly and Company |
| 状态 | 已完成 |
| 受试者人数 | 13,299 人 |
| 干预（药物） | Tirzepatide, Dulaglutide |
| 开始日期 | 2020年5月29日 |
| 完成日期 | 2025年6月12日 |
| 结果公布日 | 2026年7月8日 |
摘要
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]
| Tirzepatide (MTD) | 801 participants |
|---|---|
| 1.5 mg Dulaglutide | 862 participants |
在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文
同一适应症的其他试验
- Cardiovascular Outcomes in Bariatric Surgery Patients With Type 2 Diabetes — The Cleveland Clinic
- Diabetes Prevention Program Outcomes Study — National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Uric Acid Lowering Trial in Youth Onset T2D — University of Colorado, Denver
- Financial Incentives And Nurse Coaching to Enhance Diabetes Outcomes (FINANCE-DM)-1 — State University of New York at Buffalo
- Continuous Glucose Monitoring Following Hospital Discharge — Kathleen Dungan
- Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on I — University of Colorado, Denver